Clovis Oncology, Inc. (CLVS)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 1.4600 |
| Open | 1.4200 |
| Bid | 1.3900 x 1100 |
| Ask | 1.4100 x 3200 |
| Day's range | 1.3500 - 1.4850 |
| 52-week range | 0.5800 - 5.0000 |
| Volume | |
| Avg. volume | 12,783,819 |
| Market cap | 203.717M |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.0840 |
| Earnings date | 01 Nov 2022 - 07 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.00 |
- Simply Wall St.
The Clovis Oncology, Inc. (NASDAQ:CLVS) Analysts Have Been Trimming Their Sales Forecasts
Today is shaping up negative for Clovis Oncology, Inc. ( NASDAQ:CLVS ) shareholders, with the analysts delivering a...
- Motley Fool
Why Clovis Oncology Stock Is Sinking Today
Shares of the cancer drugmaker Clovis Oncology (NASDAQ: CLVS) are under pressure yet again today. After this latest dip, Clovis' stock is down by over 46% for the year. The biotech released its 2022 second-quarter earnings report ahead of the opening bell Monday morning, and its latest financial results aren't a hit with shareholders.
- Zacks
Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Miss
Clovis (CLVS) incurs a wider-than-estimated loss in second-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts. CLVS faces the risk of a cash crunch.
© 2022 Yahoo. All rights reserved.
